Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years. Market Analysis and Insights: Global Immune Thrombocytopenia Drugs Market The global Immune Thrombocytopenia Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Thrombocytopenia Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Thrombocytopenia Drugs market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Thrombocytopenia Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Thrombocytopenia Drugs market. Global Immune Thrombocytopenia Drugs Scope and Market Size Immune Thrombocytopenia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type Thrombopoietin Receptor Agonists (TPO-RAs) Corticosteroids Intravenous Immunoglobins (IVIGs) Other Drugs Segment by Application Biotechnology and Pharmaceutical Companies Hospitals and Diagnostic Centers Academic Institutes and Research Organizations By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company Amgen Inc. CSL Ltd. Horizon Therapeutics Plc Merck & Co., Inc. Novartis AG Rigel Pharmaceuticals Inc.
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Thrombopoietin Receptor Agonists (TPO-RAs) 1.2.3 Corticosteroids 1.2.4 Intravenous Immunoglobins (IVIGs) 1.2.5 Other Drugs 1.3 Market by Application 1.3.1 Global Immune Thromb